Trevi Therapeutics Approaches Critical Financial Update

Investors are closely monitoring Trevi Therapeutics (TRVI) as the biopharmaceutical company prepares to release its third-quarter 2025 financial results this Wednesday. The market’s primary focus remains fixed on developmental progress for Haduvio, the firm’s experimental chronic cough treatment, with stakeholders anticipating significant updates regarding the drug’s advancement.

Market analysts project Trevi will report a loss of $0.10 per share for the third quarter. This follows the company’s previous quarterly performance, where it slightly exceeded expectations with a loss of $0.09 per share. Historical trading patterns indicate TRVI shares have typically experienced price movements of up to 8.5% following earnings announcements, presenting both substantial opportunity and risk for position holders.

Development Read more...